Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator
Abstract Dorzagliatin is a novel allosteric glucokinase activator targeting both pancreatic and hepatic glucokinase currently under clinical investigation for treatment of type 2 diabetes (T2D). This study aimed to investigate the effect of renal impairment (RI) on dorzagliatin's pharmacokineti...
Saved in:
Main Authors: | Jia Miao (Author), Ping Fu (Author), Shuang Ren (Author), Chao Hu (Author), Ying Wang (Author), Chengfeng Jiao (Author), Ping Li (Author), Yu zhao (Author), Cui Tang (Author), Yuli Qian (Author), Rong Yang (Author), Yanli Dong (Author), Jing Rong (Author), Yaohui Wang (Author), Xiaowei Jin (Author), Yu Sun (Author), Li Chen (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists
by: Yixin Ren, et al.
Published: (2022) -
Impaired β-cell glucokinase as an underlying mechanism in diet-induced diabetes
by: Brian Lu, et al.
Published: (2018) -
Genetic and clinical characteristics of Chinese children with Glucokinase-maturity-onset diabetes of the young (GCK-MODY)
by: Xiuzhen Li, et al.
Published: (2018) -
Decreased expression of hepatic glucokinase in type 2 diabetes
by: Rebecca A. Haeusler, et al.
Published: (2015) -
A glucokinase-linked sensor in the taste system contributes to glucose appetite
by: Sandrine Chometton, et al.
Published: (2022)